Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1104 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| FGFR1, FGFR2, FGFR3 & TWIST1 Related Craniosynostosis Panel | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Included Tests | ||||||||||||||||||||||||||||||
| FGFR1 Exon 10, FGFR2 Exons 8 & 10, FGFR3 Exons 7 & 10 and TWIST1 only | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 1 to 2 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Sanger Sequencing | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
FGFR1, FGFR2, FGFR3 & TWIST1 related craniosynostosis panel - The craniosynostosis syndromes are a group of disorders sharing the premature fusion of one or more sutures of the skull. Often additional anomalies are associated. There are seven craniosynostosis syndromes caused by mutations in three fibroblast growth factor receptor genes: FGFR1, FGFR2 and FGFR3. They include Apert syndrome (MIM 101200), Beare-Stevenson cutis gyrata syndrome (BSTVS; MIM 123790), Crouzon syndrome (MIM 123500), Crouzon syndrome with acanthosis nigricans (CAN; MIM 612247), Jackson-Weiss syndrome (JWS; MIM123150), Muenke Syndrome (MNKES; MIM 602849) and Pfeiffer syndrome (MIM 101600). All are autosomal dominant. Penetrance varies with the specific craniosynostosis type. Many FGFR mutations are associated with advanced paternal age. Craniosynostosis, type 1 (CRS1; MIM 123100) is an autosomal dominant disorder caused by mutations in the TWIST1 gene. TWIST1 encodes a helix-loop-helix transcription factor (Twist-related protein 1) whose downstream targets include FGFRs, RUNX2 and osteoblast marker genes. Craniosynostosis without additional findings is the defining feature of CRS1. Intelligence is reported to be normal and the skull is reported to have a beaten copper appearance. Penetrance is apparently not complete as some carriers of TWIST1 mutations have been reported to be unaffected. Mutations in the TWIST1 gene also cause Saethre-Chotzen syndrome (SCS; MIM 101400) and Robinow-Sorauf syndrome (MIM 180750). |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| FGFR1, FGFR2, FGFR3, TWIST1 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 101200, 101600, 123100, 123150, 123500, 123790, 602849, 612247 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Craniosynostosis and Craniofacial Disorders | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.